Turn your website into a research center by adding headline feeds and a magazine article search engine covering topics relevant to your site.

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

See Also

Health Health / Illness, Injury & Treatments Health / Medical Practice Science & Technology / Biology & Life Sciences

Current Medical Articles

PHONE+ July 2, 2009	Case Study: SRSsoft Provides Customer Service at Optimum Speed SRSsoft integrates Optimum Lightpath's Ethernet-based communications solutions to maintain it's fast response time despite it's increasing number of clients.
The Motley Fool July 2, 2009 Robert Steyer	At Last, a Heartening Drug Approval French drug giant sanofi-aventis gets FDA approval for a drug to treat an erratic heartbeat.
The Motley Fool July 2, 2009 Brian Orelli	Squeezing Blood From a Half-Dollar Johnson & Johnson is investing $1 billion in Elan in exchange for an 18.4% stake in the company.
The Motley Fool July 2, 2009 Brian Orelli	Deal Struck, Shares Stuck Acorda Therapeutics secured a decent upfront payment to license the ex-U.S. rights to its multiple sclerosis drug, Fampridine-SR, from the perfect partner. Unfortunately, investors still smacked the stock down nearly 15% yesterday.
The Motley Fool July 1, 2009 Brian Orelli	The Meat of a One-Drug Wonder AMAG announces that its iron replacement, Feraheme, was approved by the Food and Drug Administration.
The Motley Fool June 30, 2009 Brian Orelli	A Cocktail for Drug Investors Drug cocktails aren't just for alchemists anymore. In many diseases they've become big business, and pharmaceutical investors would be smart to pay attention.
The Motley Fool June 30, 2009 Brian Orelli	Here We Go Again With Tysabri The number of patients on Biogen Idec's and Elan's multiple sclerosis drug, Tysabri, that have gotten progressive multifocal leukoencephalopathy since the drug was reintroduced to the market has reached double digits.
The Motley Fool June 30, 2009 Brian Orelli	One-Drug Wonders Deserve a Spot in Your Portfolio Looking a little more appetizing these days.
The Motley Fool June 30, 2009 Brian Orelli	Following the Pack to Future Returns Mylan's playing catch up, but there's room for more.
The Motley Fool June 30, 2009 Brian Orelli	Johnson & Johnson Inflames Abbott $1.67 billion is one hefty reward.
The Motley Fool June 29, 2009 Brian Orelli	REMS: Not Just for Sleeping Anymore Risk Evaluation and Mitigation Strategies is saving drugmakers from going into a deep sleep while they wait for Food and Drug Administration approval of their drugs.
The Motley Fool June 29, 2009 Brian Orelli	Funding From an Unlikely Place Nonprofits still have money, and they seem willing to fork it over to for-profit drug companies.
The Motley Fool June 29, 2009 Brian Orelli	Another Day, Another Rumored Suitor The rumors surrounding Elan's strategic review and its suitors just keep getting weirder.
The Motley Fool June 29, 2009 Brian Orelli	Lantus Results: Reply Hazy, Try Again Later Drugmaker Sanofi's problems become murkier. Investors are relieved that the data is out -- Sanofi is up about 4.5% at the moment -- but it seems prudent to be cautious here.
The Motley Fool June 29, 2009 Brian Orelli	Gilead Says "Pleeeease." EU Says "Well, OK." This appeal actually resulted in an approved drug.
The Motley Fool June 29, 2009 Brian Orelli	Your Company Has Been Raided. What Now? Lately, investors have had to worry about pharmaceutical companies keeping their drugs on the market.
The Motley Fool June 26, 2009 Brian Orelli	Rumors and Safety Issues -- One Bad Combination There are rumors floating around that a study will show that use of Sanofi's insulin product, Lantus, has an increased risk of cancer.
The Motley Fool June 26, 2009 Brian Orelli	Looking for a Sliver of the Me-Too Pie Another diabetes drug is close to hitting the market.
The Motley Fool June 26, 2009 Brian Orelli	Novartis Leads the Pack Biosimilars come to Japan; will the U.S. be next? In the U.S., the main hang-up is how much guaranteed patent protection branded biologics will be given.
The Motley Fool June 26, 2009 Brian Orelli	Change at Top Looks Good for Bottom Line Investors welcome Boston Scientific's new boss.
The Motley Fool June 26, 2009 Brian Orelli	The $16 Billion Market That Could Make You Rich A large market just waiting to be taken over.
BusinessWeek June 25, 2009 Catherine Arnst	The Family Doctor: A Remedy for Health-Care Costs? How making primary-care physicians the center of America's health-care system could drive down costs.
The Motley Fool June 25, 2009 Brian Orelli	Loss of a Settlement Option Earlier this month the Federal Trade Commission came out with a report arguing for limited patent protection for drugs made by biotech companies. Now it's ratcheting up its complaints about pharmaceutical and generic-drug companies as well.
The Motley Fool June 25, 2009 Brian Orelli	Pfizer Gets a Double After a couple of disappointing trials for Pfizer's Sutent, investors get some good news about the drug.
InternetNews June 24, 2009 Kenneth Corbin	CTIA Seeking Mobile Health Care Mandate With an eye toward stimulus funds, wireless trade association convenes medical experts and policy makers to talk up remote-monitoring technologies.
The Motley Fool June 24, 2009 Brian Orelli	This Just Makes Me Sick! GlaxoSmithKline's anti-nausea medication Rezonic's marketing approval was turned down by the Food and Drug Administration, reason unknown.
The Motley Fool June 24, 2009 Brian Orelli	Boston Scientific Helps Itself ... and Its Rivals Boston Scientific released positive results from a clinical trial testing its heart devices, but unfortunately the data is likely to help its competitors as well.
The Motley Fool June 23, 2009 Brian Orelli	A Pharma Proposal Homer Simpson Could Love Drug companies have pledged to hand out $80 billion worth of doughnut holes over the next decade to low- and middle-income seniors, complete with a side of good PR.
The Motley Fool June 23, 2009 Brian Orelli	Wonder Drug! Maybe? Get the facts before jumping on this one.
The Motley Fool June 22, 2009 Jim Mueller	Dendreon: Cash Out or Keep Riding Up? Given Dendreon's rise this year and Provenge's prospects, what should a prudent investor do?
Fast Company July 2009 Kate Rockwood	How BodyMedia Is Making Fitness Data Personal Ivo Stivoric has developed wearable fitness sensors for clinical patients for more than a decade. Responding to demand, BodyMedia introduced its GoWear fit line for consumers last year.
Fast Company July 2009 Kate Rockwood	Gadi Amit on Designing a Lifestyle App for the Networked Body The Fitbit Tracker is an activity monitor that calculates your steps, calories burned, and sleep patterns.
Fast Company July 2009 Kate Rockwood	How Mayo Clinic and Microsoft Are Empowering Patients The Mayo Clinic Health Manager free Web application, launched in April, supports data from health-monitoring devices, stores family medical records using Microsoft's HealthVault, and offers guidance and reminders from the Mayo Clinic.
Fast Company July 2009 Kate Rockwood	How Body Sensors Are Gaming the Health System A social online game called Wellness Partners awards virtual "energy points" for real-world physical activity.
Fast Company July 2009 Kate Rockwood	How the Networked Body Is Reinventing the Consumer A short conversation with Leslie Saxon, who has worked in the field of networked health monitoring for 17 years.
Fast Company July 2009 Kate Rockwood	How Toumaz Is Building a Complete Ecosystem for the Networked Body Alison Burdett developed the Sensium, a tiny chip-based wireless system for medical-device developers; it consumes up to 100 times less energy than other chips for wireless body-monitoring networks.
Fast Company July 2009 Zachary Wilson	Why Walgreens Is Building Its Own Universal Health-Care System Walgreens, the $59 billion drugstore giant, is building its own universal health-care system, with more than 700 retail and corporate clinics.
The Motley Fool June 19, 2009 Brian Orelli	Dendreon Is No Dot-Com Story ... Yet Is Dendreon a bad buy at today's prices? Not if it gets cancer treatment Provenge approved. And there's the risk.
The Motley Fool June 19, 2009 Robert Steyer	MannKind Needs More Leaps Getting FDA approval for its inhaled-insulin product is only one hurdle for this start-up pharmaceutical.
The Motley Fool June 19, 2009 Brian Orelli	Comparative Medicine Could Sink Your Stocks The government's plan will have a very unpredictable effect on companies.
The Motley Fool June 18, 2009 Brian Orelli	Your Stocks Just Got Riskier It's been a busy week for the Food and Drug Administration, and not in the bust-out-the-champagne-we-got-an-approval way. Is the FDA cracking down on pharmaceutical companies?
The Motley Fool June 18, 2009 Daniel Harrison	Is Dendreon Just a Dot-Com Story at This Price? The stock has had a really good year, but now it may be time to lock in the gains.
BusinessWeek June 17, 2009 Catherine Arnst	Why the AMA Will Likely Support Health-Care Reform Obama's plan might lower specialists' pay, but it would help primary-care doctors, save the industry billions, and please voters.
Pharmaceutical Executive June 1, 2009	Pay For Play The P4P movement is here. Pharma marketers, it's time to take note.
Pharmaceutical Executive June 1, 2009	Stealth Pharmas These noteworthy pharmas and biotechs generally fly under the radar (ergo "stealth") of the mainstream media.
Pharmaceutical Executive June 1, 2009	Emerging Leaders 2009: The Faces of Innovation Meet 2009's emerging leaders - 27 industry pioneers under age 45 who are bringing new ideas to life.
Pharmaceutical Executive June 1, 2009 John F. Kouten	On the Right Pathways With staggering year-over-year growth, biosimilars are "the future of medicine." Marketers must position their companies for the inevitable changes. President Barack Obama has pledged support for legislation governing biosimilars.
Pharmaceutical Executive June 1, 2009 Michael Maher	Learning to Relate A multi-phase implementation strategy can debunk the myth that social media won't work for pharma.
Pharmaceutical Executive June 1, 2009 Patrick Clinton	High School Justice FDA slaps down Cheerios and forces pharma companies that use Google to make technical changes no consumer will ever notice. Big whoop.
The Motley Fool June 17, 2009 Brian Orelli	Savient Saves and Moves Up The FDA advisory panel gives Savient's Krystexxa a passing grade.
The Motley Fool June 16, 2009 Brian Orelli	Going Viral, but Not in a Good Way Genzyme's manufacturing problems with viruses underscore the complexity of manufacturing biologic drugs compared to small molecule drugs.
Chemistry World June 15, 2009 Matt Wilkinson	Concert arranges billion dollar GSK deal US-based Concert Pharmaceuticals has inked its first commercialization deal granting GlaxoSmithKline access to six deuterium-modified drugs
Inc. June 2009 Nicole Marie Richardson	Innovation: CardioMEMS EndoSure Sensor CardioMEMS creates body sensors that monitor cardiovascular health.
Chemistry World June 5, 2009 Anna Lewcock	Pharma's new world order So-called 'pharmerging' markets will contribute over half of the growth of the global pharmaceutical market this year, according to market analysts.
Chemistry World June 2009 Derek Lowe	Column: In the pipeline The author wonders about pharmaceutical companies' motives for collaboration
Chemistry World May 21, 2009 Matt Wilkinson	Big Pharma set for generics boost Pharmaceutical firms have been rushing to ensure they minimize their losses by expanding their generics businesses and reach into emerging markets.
Chemistry World May 21, 2009 Rebecca Trager	FDA gets new chief The US Food and Drug Administration's (FDA) new commissioner, Margaret Hamburg, will be the second woman to ever lead FDA
There are 5914 old articles available for this category.